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Conclusions: The obtained results have shown the possible relation 
between the GSTT1 genotype and the level of chromosome aberrations 
in somatic cells of lung cancer patients. 
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Background: The clinical application of monoclonal antibodies has 
been well established for the treatment of various human cancers. 
However, there were a few reports which showed the effectiveness of 
antibody therapy against lung cancer. In the present study, we report a 
novel cell surface antigen which was identiﬁed by SEREX method by 
using the antibody (Ab) derived from tumor-inﬁltrating B lymphocytes 
(TIB).
Methods: A904L, a lung large cell carcinoma cell line, was established 
from patient A904. The surgically resected lung cancer specimens of 
the patient was xenotransplanted into SCID mice. SCID mice engrafted 
with the lung cancer were bled by retro-orbital venipuncture every 2 
weeks and the amount of human immunoglobulin produced from TIB 
in the blood was analyzed by ELISA. A cDNA library was constructed 
from A904L cells and immunoscreening was performed by SEREX 
method by using IgG derived from TIB. 
Results: As a result of the cDNA library screening, 22 different antigen 
genes were isolated. A homology search through BLAST database 
revealed that the 22 antigen genes included 13 function-known and 9 
function-unknown genes. Identiﬁed antigens were sequenced and 4 of 
these antigens had extracellular domain. We designated one of these 
antigens as UOEH-LC-1. The mRNA expression of UOEH-LC-1 was 
investigated in lung cancer cell lines, normal tissues and tissue speci-
mens of lung cancer, using quantitative RT-PCR. UOEH-LC-1 was 
overexpressed in 5 of 11 (45.5%) lung cancer cell lines and also was 
overexpressed in 9 of 15 (60%) lung cancer tissues compared with the 
paired normal lung tissues. mRNA of UOEH-LC-1 was expressed in 
heart, kidney, liver, prostate, testis and thyroid gland among the panel 
of 20 normal tissues. Immunohistochemical evaluation of UOEH-LC-
1 was performed in the lung cancer tissue specimens by using rabbit 
polyclonal Ab against UOEH-LC-1. Seven out of 28 (25.0%) lung 
cancer specimens demonstrated positive staining on the cell surface. 
Flow cytometry analysis using the polyclonal Ab revealed positive 
staining on lung cancer cell lines which were positive expression 
of mRNA of UOEH-LC-1, however negative staining for a cell line 
with negative mRNA expression of UOEH-LC-1. The suppressive 
effect of polyclonal Ab was examined in SCID mice model xenotrans-
planted with UOEH-LC-1 positive lung cancer cell line (A904L). The 
administration of anti-UOEH-LC-1 Ab inhibited the growth of A904L. 
Complement-dependent-cytotoxicity (CDC) of anti-UOEH-LC-1 Ab 
was observed against UOEH-LC-1 positive 2 cell lines, but not against 
a UOEH-LC-1 negative lung cancer cell line. One possible mechanism 
of an anti-tumor effect of anti-UOEH-LC-1 Ab was mediated by the 
CDC activity. 
Conclusions: UOEH-LC-1 was overexpressed on the cell surface of 
lung cancer. Furthermore, the antibody against UOEH-LC-1 had anti-
tumor activity both in vitro and in vivo. The growth inhibitory effects 
of the Ab on lung cancer indicates the usefulness of UOEH-LC-1 as an 
effective target for antibody-based immunotherapy.
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Background: It has been reported that there are several gender-associ-
ated differences in clinicopathological features of non-small cell lung 
cancer (NSCLC). The aim of this study was to measure the relative 
expression levels of estrogen receptor (ER) mRNA in NSCLC tissue, 
and to characterize the role of estrogen in gender differences. 
Methods: The ER mRNA expression levels in 20 parafﬁn-embedded 
samples of surgically resected NSCLC tissue were retrospectively de-
termined by RT-PCR. The ER mRNA expression levels were prospec-
tively measured in snap-frozen materials of both lung cancer tissue and 
normal lung in patients with adenocarcinoma. In both studies, the gene 
expression levels were determined as the relative values to the expres-
sion level of GAPDH. 
Results: In parafﬁn-embedded materials of NSCLC, the ERα mRNA 
expression level was signiﬁcantly higher in females (p=0.0003, versus 
males), non-smokers (p=0.0001, versus former or current-smokers), 
and adenocarcinoma (p=0.003, versus non-adenocarcinoma). The 
ER β mRNA expression level was signiﬁcantly higher in females 
(p=0.02, versus males) and non-smokers (p=0.02, versus former or 
current-smokers). A high expression level of ERα was associated with 
well-differentiated adenocarcinoma of females. In snap-frozen normal 
lung tissues, the ERα mRNA expression levels in males (n=4) and in 
females (n=3) were 9.85±12.80×10-3 and 8.90±5.90×10-3, respectively. 
On the other hand, the ERα mRNA expression levels in adenocarci-
noma tissue had the tendency to be higher in females than in males 
(15.87±22.57×10-3 versus 6.40±11.0×10-3). 
Conclusions: ERs were highly expressed in female pulmonary adeno-
carcinoma tissue. The results suggest that estrogens play a role in the 
development of female pulmonary adenocarcinoma, and are associated 
with the gender-differences in NSCLC. 
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The Fas/FasL system is a primary mediator of apoptosis. It plays an im-
portant role in the development of lung cancer. Osteoprotegerin (OPG) 
blocks endothelial cell apoptosis through binding to TRAIL (TNF 
related apoptosis inducing ligand). Elevated serum levels of soluble Fas 
(sFas), soluble FasL (sFasL) and OPG have been observed in patients 
with many kinds of cancer. The dates about levels of sFas, sFasL and 
OPG in lung cancer are poor. The present study was carried out to ana-
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lyze the levels of sFas, sFasL and OPG in lung cancer in relation to the 
histological type of the tumor, clinical stage, response to therapy. The 
study included 48 patients (NSCLC- Non Small Cell Lung Cancer) and 
15 healthy subjects as controls. Peripheral venous blood samples were 
collected before and after chemotherapy. sFas, sFasL and OPG serum 
levels were measured with a Elisa kits (R&D; Bender MS.).
The mean serum values of OPG, sFas and sFasL were signiﬁ-
cantly higher in cancer patients than in controls (OPG: 4,2±1,2 vs 
3,16±0,8pmol/l; sFas: 1253,0±389 vs 981,7±272 pg/ml; sFasL: 
352,3±47 vs 556,7±84 pg/ml). There was no difference of OPG in 
relation to response to therapy. sFas mean levels observed at the end of 
chemotherapy were higher in responders patients than in the progressed 
ones (p=0,008). The metastatic patients had higher levels of OPG and 
sFas than those without metastases. The mean serum value of sFas 
were signiﬁcantly higher in no weight loss patients (p=0,03). In our 
opinion, OPG, sFas and sFasL levels may be a helpful during therapy 
of lung cancer, but their clinical signiﬁcance needs further investiga-
tions.
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Neoangiogenesis plays a vital role in the growth of a cancerous tumor 
and the development of metastasis. Vascular endothelial growth fac-
tor is a main agent triggering neoangiogenesis. The family of VEGF 
consists of many growth factors, e.g., VEGF A, VEGF B, VEGF C, 
VEGF D. VEGF C and VEGF D are relatively less known. The recep-
tor of VEGF R2 is a main receptor taking part in neoangiogenesis. The 
present study was carried out to analyze the levels of VEGF C, VEGF 
D and sVEGFR2 in lung cancer in relation to the histological type of 
the tumor, clinical stage, response to therapy. The study included 80 
patients (36 SCLC, 44 NSCLC) and 20 healthy subjects as controls. 
Peripheral venous blood samples were collected before and after 
chemotherapy. VEGF C, VEGF D and sVEGFR2 serum levels were 
measured with a sandwich enzyme immunoassay using commercial kits 
(R&D System). Serum levels of VEGF C, VEGF D were signiﬁcantly 
higher in both NSCLC and SCLC groups in comparison with controls 
(VEGF C: NSCLC: 7,8±2,4 vs 4,56±1,8 ng/ml; SCLC: 7,96±2,7 vs 
4,56±1,8; VEGF D: NSCLC: 1,02±0,5 vs 0,57±0,1 ng/ml; SCLC: 
1,04±0,8 vs 0,57±0,1; sVEGFR2: NSCLC: 12,63±3,1 vs 15,64±5,2; 
SCLC: 13,42±3,8 vs 15,64±5,2 ng/ml). VEGF C concentration de-
creased after chemotherapy, whereas VEGF D concentration was at the 
same level. No correlation was found between VEGF C and VEGF D 
concentrations and the effect of treatment. Patients with lung cancer 
and progression after chemotherapy (PD) had the higher concentration 
of sVEGFR2 than patients with partial remission (PR) (13,19±2,7 vs 
11,74±2,7 ng/ml). The levels of sVEGF R2 were lower before and after 
treatment than in controls (p<0,05). No relation was found between 
VEGF C, VEGF D and sVEGF R2 concentrations and the histological 
type and staging of lung cancer. 
Summing up, serum concentrations of VEGF C, VEGF D were higher 
in patients with lung cancer both before and after chemotherapy than 
in healthy people, whereas sVEGF R2 concentration is lower than in 
healthy people. An increase in concentration of sVEGF R2 during che-
motherapy may suggest progression of the disease. However, it requires 
further examinations. 
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Background: Metastatic spread constitutes the primary source of mor-
bidity and mortality of Non Small Cell Lung Cancer (NSCLC). Migra-
tion of cells is an important step in the metastatic process. A successful 
anti-migration strategy would be applicable in both the adjuvant setting 
(prevent primary metastasis) and the metastatic setting (inhibit further 
metastatic disease developing). One possible anti-migration approach is 
inhibition of the CXCR4/ SDF-1 axis.
CXCR4 is a well described G protein coupled chemokine receptor that 
has a role in cellular movement. CXCR4 and its ligand, stromal cell 
derived factor-1 (SDF-1), play a critical role in leukocyte trafﬁcking 
and homing of hematopoietic stem cells. Binding of CXCR4 by SDF-
1 results in the activation of many downstream pathways including 
mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and 
calcium mobilization. SDF-1 is constitutively released by stromal cells 
from bone marrow, lung and liver which are common sites of tumor 
metastasis. In turn, CXCR4 is highly expressed on NSCLC tumor cells. 
However, the role of CXCR4 in the migration of NSCLC cells has not 
been extensively explored. We investigated the effect of modulation of 
the CXCR4/SDF-1 axis would have on lung cancer cell migration.
Methodology: Two human NSCLC cell lines (H460 and H1299) were 
used. CXCR4 expression was assessed by western blotting and ﬂow cy-
tometry. Migration patterns were investigated using a 48-well Boyden 
chamber. Cells added to the upper wells were separated from the lower 
wells by a coated polycarbonate ﬁlter. Chemoattractants (increasing 
concentrations of fetal calf serum (FCS), SDF-1) and/or inhibitors were 
added to the lower wells. After incubation, non-migrating cells on the 
top side of the ﬁlter were wiped off. The migrating cells, adherent to 
the underside of the ﬁlter, were stained with hematoxylin and counted 
microscopically at 20x magniﬁcation. 
Results: Both NSCLC cell lines express CXCR4 on their surface. 
Filters containing 8um pores impeded cell migration compared to those 
with 12um sized pores. Both cell lines migrated across the membrane 
in response to increasing concentrations of FCS, with 20% being the 
optimal concentration. Stimulation of CXCR4 by an SDF-1 agonist ap-
pears to stimulate migration of both NSCLC cell lines, while inhibition 
of this axis by anti CXCR-4 antibodies reduced the proportion of cell 
migration across the Boyden Chamber membrane by more than 60%. 
This inhibition persisted even in the presence of 20% FCS or SDF-1. 
Conclusions: Inhibition of the CXCR4/SDF-1 axis appears to inhibit 
the migration of these NSCLC cells in vitro. The CXCR4 axis may 
play a role in inﬂuencing the migrational behavior of NSCLC cells 
in vivo. Additional experiments to assess the role of small molecular 
inhibitors of CXCR4 are currently underway. These results suggest that 
use of CXCR4 inhibition strategies may be a useful therapeutic tool to 
